Professor Mark Bullimore of the University of Houston, Texas USA, tells us more on the complex topic of 0.01% atropine, including its stability as a compound, and takes us on a short journey through chemistry explaining how current studies are using novel formulations to address this issue. Have you heard of ‘heavy water’? I hadn’t, until now! Mark advocates for you to ‘be the doctor’, using the side effects as a gauge of drug efficacy, and even suggests a novel clinical approach in practice to determine the individual patient’s response and tolerance. We also discuss the mismatch (or otherwise) of refractive and axial length control results in atropine studies which don’t appear to be the case in studies of optical interventions, along with communicating the ‘why’ of myopia management through the dioptric effect of control.
Mark Bullimore is a consultant for a number of companies, including Alcon, CooperVision, Essilor, Eyenovia, Genentech, Johnson & Johnson Vision, Novartis, and is the sole owner of Ridgevue Publishing, Ridgevue Technologies, and Ridgevue Vision.
Dr Kate Gifford is a clinical optometrist, researcher, peer educator and professional leader from Brisbane, Australia, and a co-founder of Myopia Profile.
This educational content is brought to you thanks to unrestricted educational grant from